[A comparative clinico-pharmacological study of adalat, foridone, siskor, lomir effects on cerebral and peripheral circulation in patients with arterial hypertension]. / Sravnitel'noe kliniko-farmakologicheskoe izuchenie vliianiia adalata, foridona, siskora, lomira na tserebral'noe i perifericheskoe krovoobrashchenie u bol'nykh arterial'noi gipertenziei.

The results of a comparative clinicopharmacological study of adalate, foridone, siskor and lomir effects on cerebral and peripheral blood flow are presented for 46 patients with arterial hypertension stage I-III. It was found that all the four drugs relieve tonicity and enhance blood flow in a. cerebri media and a. carotis communis. Lomir and adalate had more potent effects on central hemodynamics. A maximal dilating effect on regional peripheral arteries was observed after a single intake of siskor and adalate, while lomir's and foridone's single doses were weaker. In course treatment with the above drugs these differences are less.

[Pharmacokinetic and pharmacodynamic effects of isradipine in patients with arterial hypertension]. / Izuchenie farmakokineticheskikh i farmakodinamicheskikh éffektov isradipina u bol'nykh arterial'noi gipertenziei.

It was established that a regular administration of isradipine is accompanied by an increase in the mean values of Cmax (by 21.7%) and AUC (by 21.8%), which leads to extension of the pharmacodynamics effects without cumulation (the values of Clt, T1/2, and Tmax remain unchanged). The maximum hemodynamic effect of isradipine upon a single administration in a single dose of 5 mg coincides with the time or reaching the maximum drug concentration in the blood (Tmax). There is a reliable correlation between the hypotensive effect, the peripheral vascular resistance, and the concentration of isradipine.

[The pharmacokinetic and pharmacodynamic characteristics of foridon during interaction with the metabolic oxidation inhibitor dopegit]. / Osobennosti farmakokinetiki i farmakodinamiki foridona pri vzaimodeistvii s ingibitorom metabolicheskogo okisleniia dopegitom.

The paper deals with some aspects of the effects produced by dopegite on the pharmacokinetics and pharmacodynamics of foridone from a group of calcium antagonists. Nineteen patients with essential hypertension received a single doses of foridone of 40 mg, then its course therapy in a dose of 90 mg/day for 2 weeks, then it was supplemented with dopegite in a dose of 750 mg/day for 2 weeks too. Supplementation of dopegite caused statistically significant changes as higher plasma concentrations of foridone and increased concentration-time curve areas, decreased total peripheral resistance and regional, and a lower spasm index. Dopegite can be used to enhance the antihypertensive effect of foridone.